Trial phase* | Ph I | Ph II | Ph III | Ph IV | Total | |||||
Characteristic | N | % | N | % | N | % | N | % | N | % |
All entries, N | 99 | 287 | 324 | 98 | 808 | |||||
Design characteristics | ||||||||||
Neither | 86 | 89 | 261 | 93 | 303 | 94 | 90 | 94 | 740 | 93 |
Adaptive | 1 | 1 | 7 | 2 | 13 | 4 | 3 | 3 | 24 | 3 |
Bayes | 10 | 10 | 12 | 4 | 5 | 2 | 2 | 2 | 29 | 4 |
Both | 0 | 0 | 2 | 1 | 0 | 0 | 1 | 1 | 3 | 0 |
Cluster randomised | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Stepped wedge | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Involves placebo | 21 | 22 | 123 | 44 | 163 | 51 | 25 | 26 | 332 | 42 |
Independent data monitoring committee | ||||||||||
No | 40 | 82 | 84 | 59 | 61 | 42 | 46 | 78 | 231 | 58 |
Yes | 9 | 18 | 59 | 41 | 84 | 58 | 13 | 22 | 165 | 42 |
Missing | 8 | 139 | 176 | 37 | 400 | |||||
Methods of dissemination | ||||||||||
Peer-reviewed scientific journal | 86 | 89 | 265 | 94 | 290 | 90 | 93 | 97 | 86 | 89 |
Submission to regulatory authority | 85 | 88 | 215 | 76 | 272 | 85 | 48 | 50 | 85 | 88 |
Conference presentation | 82 | 85 | 253 | 90 | 271 | 84 | 89 | 93 | 82 | 85 |
Internal report | 71 | 73 | 212 | 75 | 259 | 81 | 60 | 63 | 71 | 73 |
Publication on website | 56 | 58 | 161 | 57 | 203 | 63 | 45 | 47 | 56 | 58 |
Other publication | 26 | 27 | 76 | 27 | 92 | 29 | 17 | 18 | 26 | 27 |
Access to raw data | 8 | 8 | 12 | 4 | 25 | 8 | 8 | 8 | 8 | 8 |
Other | 12 | 12 | 47 | 17 | 48 | 15 | 18 | 19 | 12 | 12 |
No plans to report or dissemination | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 |
Areas of PPI activity† | ||||||||||
Design of the research | 26 | 27 | 82 | 29 | 39 | 12 | 50 | 52 | 26 | 27 |
Management of the research | 10 | 10 | 34 | 12 | 28 | 9 | 31 | 32 | 10 | 10 |
Undertaking the research | 14 | 14 | 47 | 17 | 36 | 11 | 29 | 30 | 14 | 14 |
Analysis of results | 1 | 1 | 15 | 5 | 7 | 2 | 12 | 13 | 1 | 1 |
Dissemination of findings | 20 | 21 | 74 | 26 | 64 | 20 | 44 | 46 | 20 | 21 |
None of the above | 53 | 55 | 149 | 53 | 223 | 69 | 35 | 36 | 460 | 58 |
REC opinion | ||||||||||
Favourable | 97 | 98 | 277 | 97 | 318 | 98 | 93 | 95 | 785 | 97 |
Favourable | 14 | 14 | 51 | 18 | 40 | 12 | 15 | 15 | 120 | 15 |
Favourable (after extra info) | 83 | 84 | 226 | 79 | 278 | 86 | 78 | 80 | 665 | 82 |
Unfavourable | 0 | 0 | 5 | 2 | 3 | 1 | 3 | 3 | 11 | 1 |
*Trial phase calculated.
†Not mutually exclusive.
CTIMP, clinical trials of investigational medicinal product; PPI, patient and public involvement; REC, Research Ethics Committee.